Melanoma: all 3,073 studies

Page 13 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00096382Phase 2Results posted
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results posted
• Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic MelanomaCompletedNCT00094107Phase 2Results posted
• Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)CompletedNCT00091572Phase 3Results posted
• Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00085423Phase 2Results posted
• Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2Results posted
• Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersCompletedNCT00074308Phase 1/2Results posted
• A Phase II Study of UCN-01 in Metastatic MelanomaTerminatedNCT00072189Phase 2Results posted
• Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic MelanomaCompletedNCT00071981Phase 2Results posted
• Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic MelanomaCompletedNCT00060333Phase 2Results posted
• Peptide Vaccination for Patients at High Risk for Recurrent MelanomaCompletedNCT00059475Phase 2Results posted
• PEG-Interferon Alfa-2b in Treating Patients With Stage IV MelanomaCompletedNCT00049530Phase 2Results posted
• Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00026221Phase 2Results posted
• Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3Results posted
• S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaCompletedNCT00006237Phase 3Results posted
• Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaCompletedNCT00003895Phase 2Results posted
• High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaCompletedNCT00003641Phase 3Results posted
• Antineoplaston Therapy in Treating Patients With Stage IV MelanomaTerminatedNCT00003509Phase 2Results posted
• Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00003224Phase 1Results posted
• Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003222Phase 2Results posted
• Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic MelanomaCompletedNCT00001832Phase 2Results posted
• Skin Cancer Among Outdoor WorkersCompletedNCT07831083
• Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in CancerActive, not recruitingNCT07796594Not applicable
• MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and ManagementCompletedNCT07757386Not applicable
• Adjuvant Therapy of Skin Melanoma With Alpha Interferon and NaderinCompletedNCT07671495Phase 2
• Digital Phenotyping of Psychological Distress in Skin Cancer PatientsWithdrawnNCT07670403
• The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant TumorsCompletedNCT07651020
• A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in JapanCompletedNCT07649252
• ctDNA for Risk Stratification in MelanomaActive, not recruitingNCT07531121
• IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaCompletedNCT07436390Not applicable
• Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma PatientsCompletedNCT07434323Not applicable
• Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK InhibitorsCompletedNCT07431489Not applicable
• Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health CentersCompletedNCT07429123
• Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient CareCompletedNCT07428954
• Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.CompletedNCT07428941
• Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant MelanomaActive, not recruitingNCT07428252Not applicable
• Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant MelanomaCompletedNCT07427953
• Circulating Tumor DNA in Melanoma PatientsActive, not recruitingNCT07422805Phase 1/2
• Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)Active, not recruitingNCT07376317Phase 2
• A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaActive, not recruitingNCT07288203Phase 2
• Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center AnalysisCompletedNCT07256184
• NG2 and DLL3 CAR-T Cells Targeting MelanomaTerminatedNCT07193966Phase 1/2
• A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.Active, not recruitingNCT07177638Not applicable
• A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Phase 1
• Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsTerminatedNCT07121829Phase 1
• Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)SuspendedNCT07102212Not applicable
• Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + BinimetinibWithdrawnNCT07092410Phase 4
• Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabCompletedNCT07091695
• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaTerminatedNCT07076550Phase 1
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationActive, not recruitingNCT07023731Phase 1/2
• UK ENcorafenib and BInimetinib Real-world Study in MelanomaActive, not recruitingNCT07022457
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesTerminatedNCT06974734Phase 1
• TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of MelanomaActive, not recruitingNCT06961786Phase 1
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2
• Exploratory Study of Inhaled Afatinib Dimaleate PK ProfileTerminatedNCT06897735Phase 1
• A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
• A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
• Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous MelanomaActive, not recruitingNCT06863870
• One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node BiopsyActive, not recruitingNCT06809491
• A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid TumorsTerminatedNCT06799533Phase 1
• Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingNCT06784648Phase 1/2
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsActive, not recruitingNCT06781983Phase 1
• A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal MelanomaActive, not recruitingNCT06717126Phase 2
• Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node BiopsyCompletedNCT06666634Not applicable
• How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.CompletedNCT06654999
• EPIC- Extracorporeal Photopheresis (ECP) for Immune-related ColitisWithdrawnNCT06646016Phase 2
• Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
• Improved Early Diagnosis in Female Pelvic Cancer With OC DetectCompletedNCT06613230
• Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersActive, not recruitingNCT06608511
• Study to Examine Lesions of the Skin Using Confocal Laser MicroscopyActive, not recruitingNCT06598137
• An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaNo longer availableNCT06590480
• Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®TerminatedNCT06587451Phase 3
• Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1CompletedNCT06586580
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaActive, not recruitingNCT06566391Phase 2
• Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsTerminatedNCT06566092Phase 1
• Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV MelanomaCompletedNCT06557291
• Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma PatientsActive, not recruitingNCT06556004Phase 1
• Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma PatientsCompletedNCT06551064Phase 1
• eFLASH for Skin Lesions of Malignant MelanomasCompletedNCT06549439Not applicable
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma PatientsActive, not recruitingNCT06540391Phase 1
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingNCT06521567Phase 1/2
• Intravenous Iron in Combination With Standard of Care Immunotherapy in MelanomaWithdrawnNCT06508827Phase 2
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainActive, not recruitingNCT06500455Phase 3
• Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With MelanomaCompletedNCT06463509
• A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationTerminatedNCT06448364Phase 1
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced CancerActive, not recruitingNCT06416085Phase 2
• Etude rétrospective Monocentrique MATRIXCompletedNCT06415929
• Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney CancerSuspendedNCT06391099Not applicable
• Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2CompletedNCT06384417Not applicable
• A Study to Test the Benefit of Vitamin B5 in Patients With MelanomaActive, not recruitingNCT06377111Phase 1
• Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma PatientsCompletedNCT06369428
• Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Active, not recruitingNCT06346067Phase 3
• A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive MelanomaCompletedNCT06337617
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsTerminatedNCT06336148Phase 1
• Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaCompletedNCT06320353Phase 3
• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1

← Melanoma overview